CEBP Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frey, U. H.
Right arrow Articles by Siffert, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frey, U. H.
Right arrow Articles by Siffert, W.
Cancer Epidemiology Biomarkers & Prevention Vol. 14, 871-877, April 2005
© 2005 American Association for Cancer Research

The T393C Polymorphism of the G{alpha}s Gene (GNAS1) Is a Novel Prognostic Marker in Bladder Cancer

Ulrich H. Frey1, Andreas Eisenhardt2, Gerd Lümmen2, Herbert Rübben2, Karl-Heinz Jöckel3, Kurt W. Schmid4 and Winfried Siffert1

1 Institut für Pharmakologie, 2 Urologische Klinik, 3 Institut für Medizinische Informatik, Biometrie und Epidemiologie and West German Tumor Centre, and 4 Institut für Pathologie, Universitätsklinikum, Essen, Germany

Requests for reprints: Ulrich H. Frey, Institut für Pharmakologie, Universitätsklinikum, Essen, Hufelandstrasse 55, D-45122 Essen, Germany. Phone: 49-201-7233459; Fax: 49-201-7235968. E-mail: Ulrich.Frey{at}uni-essen.de


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The G protein G{alpha}s pathway is linked to proapoptotic signaling in cancer cell lines. To assess the role of the GNAS1 locus encoding G{alpha}s as a genetic factor for disease progression of transitional cell carcinoma (TCC) of the bladder, we genotyped the synonymous T393C polymorphism in 254 patients with TCC (minor allele frequency: 0.43) to examine a potential association between genotypes and disease progression. Using Kaplan-Meier estimates to calculate 5-year probabilities of follow-up, we could show that progression-free survival, metastasis-free survival, and cancer-specific survival was significantly increased in TT genotypes (56%, 84%, 82%) compared with CC genotypes (35%, 53%, 58%). In multivariate Cox proportional hazard analysis, the T393C polymorphism was an independent prognostic factor for clinical outcome. Homozygous CC patients were at highest risk for progression [odds ratio (OR), 1.94; P = 0.020], metastasis (OR, 3.49; P = 0.005), and tumor-related death (OR, 2.49; P = 0.031) compared with TT genotypes. Heterozygous patients had an intermediate risk compatible with a gene-dose effect. Real-time PCR analysis of urothelial tumor tissue as well as adipose and heart tissue revealed that G{alpha}s mRNA expression was highest in TT genotypes, indicating a proapoptotic effect in these genotypes. In conclusion, the GNAS1 T393C status associated with differential G{alpha}s mRNA expression is a novel independent prognostic marker for clinical outcome supporting a functional role of G{alpha}s in bladder cancer progression.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Transitional cell carcinoma (TCC) of the bladder is the fourth most frequent cancer in the United States with ~57,400 new cases expected in the year 2003 (1). At first presentation, roughly 70% of cases are classified as superficial disease, whereas 30% of tumors have already invaded the bladder wall (2, 3). Ninety-five percent of urothelial neoplasms are of the transitional cell type (TCC). The overall 5-year survival rate for all patients with urothelial cancer is 81%; however, this rate varies greatly depending on multiple factors, including disease stage, and mutations in tumor suppressor genes (4, 5). Within the United States, TCC is twice as common among White people compared with Blacks, and incidence and mortality directly increases with age (1, 6). Still, the best established and routinely used clinical markers to predict prognosis are depth of tumor invasion, presence or absence of lymph node and distant metastases, and tumor differentiation (7). Tumor progression is thought to result from the accumulation of multiple genetic alterations, including the activation of oncogenes, loss of distinct chromosomal regions, and inactivation of tumor suppressor genes, such as p53 and Rb (8-10). Inactivation of these genes may, for example, result in impaired apoptosis of cancer cells, which contributes to tumor progression.

Recent investigations have shown that an increased concentration of the intracellular second messenger cyclic AMP (cAMP) promotes apoptosis in several cell types including leukemic cells (11), ovarian cancer cells (12), and lymphoma cells (13). Elevation of cAMP results from signal transduction from G protein–coupled receptors to the G{alpha}s protein, which in turn activates its effector adenylyl cyclase to produce cAMP (14). A potential role of G{alpha}s in promoting apoptosis has been proposed through experiments in which increased expression of G{alpha}s has been shown to activate the adenylyl cyclase signal transduction cascade resulting in an accumulation of cAMP (15, 16). The G{alpha}s subunit is encoded by the gene GNAS1, which is mapped to chromosome 20q13 and consists of 13 exons. Somatic activating mutations of GNAS1 have been implicated in the etiology of McCune Albright Syndrome (17) and sporadic, isolated endocrine tumors (18-20), which principally supports a role of GNAS1 in tumor initiation and/or progression. Moreover, a common synonymous single nucleotide polymorphism in exon 5 of the gene GNAS1 (T393C) was associated with hypertension although its functional role was not elucidated (21-23). The aim of the present study was to investigate a potential association between genotypes of the T393C polymorphism and disease progression in patients with TCC. Moreover, we investigated genotype-dependent expression of G{alpha}s mRNA in different tissues to potentially uncover a functional mechanism that could explain the observed results.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Patients
Tumor tissue was stored from patients with bladder cancer (n = 389), who were treated by either transurethral resection and/or cystectomy for TCC of the bladder in the years between 1989 and 2001 at the Department of Urology at the University of Essen and who consented to tissue storage. This group comprised 290 men and 109 women. The mean age at first presentation was 64.2 ± 10.8 years and 153 patients were current smokers at primary diagnosis of TCC (Table 1). In collaboration with the affiliated primary urologists and general practitioners, we were able to work up the follow-up of 254 individuals, who then were finally included into the study. All patients were White Germans of Caucasian ethnicity. Another prerequisite for entry into the study was that histopathologic confirmation of TCC of the bladder as well as grading and staging were available. The ethics committee of the Essen University Hospital approved the study protocol and all patients provided written informed consent.


View this table:
[in this window]
[in a new window]
  		Table 1. Demographic comparison of the whole group and the study group

 
The tissue was placed into a plastic vial and snap-frozen in liquid nitrogen for storage. The tumors were staged and graded by standard histologic analysis according to the guidelines of the International Union Against Cancer (24). All patients were screened for the presence of metastasis by abdominal ultrasound and chest X-ray before surgical procedure. In the case of locally advanced disease (stage ≥ pT2), patients received an abdominal CT scan.

Clinical Data
The medical records of all patients were reviewed and follow-up data were collected in cooperation with the responsible urologist and/or family physician. The data were evaluated for the end points tumor progression, metastasis, tumor-related deaths, and overall survival. We assessed smoking habits at the time of hospitalization (yes versus no), but data on smoking history or pack-years were not routinely available. The cause of death was recorded using both hospital files and information from the responsible urologist/family physician. The last clinical assessment was used to define the follow-up period. The mean follow-up period was 45.2 months. Progression was defined as an increase in stage, occurrence of metastasis, or local recurrence after cystectomy or death due to bladder cancer. If a patient was initially lost to follow-up, we consulted the municipal registry to assess survival.

Genotyping
DNA was extracted from native tumor tissue using a commercially available kit (QIAAmp, Qiagen, Hilden, Germany). Genotypes for the T393C polymorphism were determined by PCR with the use of the following primers: forward primer 5'-CTCCTAACTGACATGGTGCAA-3' and reverse primer 5'-TAAGGCCACACAAGTCGGGGT-3'. After denaturation at 94°C, 35 cycles of DNA amplification were done using Taq PCR Mastermix (Eppendorf, Hamburg, Germany) at 94°C for 45 seconds, 58°C for 40 seconds, and 72°C for 45 seconds. The 345 bp PCR products were digested using the restriction enzyme FokI and analyzed on a 2% agarose gel. The unrestricted products (345 bp) represent the TT genotype; the completely restricted products (259 and 86 bp) represent the CC genotype.

Tissue Material
Tumor specimens from patients undergoing transurethral resection or cystectomy for bladder cancer was snap-frozen in liquid nitrogen directly after dissection. Adipose tissue was obtained from 45 patients undergoing mamma reduction or gastric banding operation. All adipose tissue samples were immediately snap frozen in liquid nitrogen. Right atrial specimens were obtained from 15 patients undergoing cardiac surgery. RNA was prepared from two independent tissue samples using the RNeasy kit (Qiagen) according to the manufacturer's instructions including DNase treatment of all samples.

Quantitative Real-time PCR
First-strand cDNA was synthesized from 0.1 to 1.0 µg of total cellular RNA with oligo-dT primers (Roche, Mannheim, Germany) by using Superscript II reverse transcriptase as recommended by the supplier (Invitrogen, Karlsruhe, Germany). Quantification of G{alpha}s was carried out by using primers 5'-GCACCATTGTGAAGCAGATG-3' and 5'-TCAATCGCCTCTTTCAGGTT-3' spanning introns 2 and 3. PCR and primers for the housekeeping gene ACTB encoding hß-actin were used as described (25). The PCR reaction mix was prepared using the Quantitect SYBR Green kit (Qiagen) following the manufacturer's instructions. PCR was done in the ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA), which detects the signal from the SYBR green during PCR. A cDNA dilution series for G{alpha}s confirmed a PCR efficiency >95% of which were comparable with the efficiency of hß-actin (25). Results were confirmed using samples from independent reverse transcription and real-time PCR reactions. The relative expression of G{alpha}s compared with ß-Actin was calculated by using the following formula: G{alpha}s / ß-Actin = 2–[Ct(G{alpha}s) – Ct(ß-Actin)], where Ct is the number of cycles at which the fluorescence signal reaches a predefined threshold. Each Ct represents the mean Ct value of each sample duplicate.

Statistical Analysis and Presentation of Data
The clinical outcomes analyzed in this study were survival, time to first progression, and time to first occurrence of metastases. As the mortality from bladder cancer directly increases with age, we used the receiver operating characteristic curve analysis for overall survival to define two age groups with ≤54 years to have a favorable and >54 years to have an unfavorable overall survival (26). Kaplan-Meier plots and the log-rank test for trend were used to evaluate the relationship between stage, age, T393C genotypes, and clinical outcome from the date of the primary diagnosis to a 5-year follow-up. Log-rank tests for T393C genotypes were adjusted for pathologic stage and comparison was done using all three genotypes unless stated otherwise. The impact of gender, tumor stage, age, and T393C genotypes as prognostic factors for the clinical outcome were analyzed by backward stepwise multivariate Cox regression analysis. Hazard ratios and 95% confidence intervals (95% CI) were calculated from the Cox regression model including all factors. Contingency tables and the Pearson's {chi}2 test were used to calculate odds ratios (OR) and 95% CI for categorical variables using T393C allele frequency numbers or genotypes as indicated. Because the T393C polymorphism shows a gene-doses effect, linear ANOVA was used for comparison of continuous variables where appropriate. Differences were regarded significant at P <0.05. All statistical analyses were done using SPSS 11.0 (SPSS, Chicago, IL) or Graphpad Prism 4.0 (Graphpad Software, San Diego, CA).

Continuous variables are given as means ± SD or ±SE as indicated. ORs are given with 95% CIs.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Demographic characteristics of the whole group and the selected case group with complete follow-up are displayed in Table 1. There were no statistically significant differences regarding demographic characteristics between both groups, indicating that the case group is representative for the whole group. Mean age at diagnosis in our sample was 62.9 years, which is only 3.5 years younger than that described in two German epidemiologic studies surveying over 3,000 and 16,000 patients, respectively (27, 28). Grading and staging was higher in our study population compared with these latter studies in which 38.9% to 54.7% were pTa, 14.9% to 25.0% pT1, 15.6% to 20.0% pT2, 8% to 10% pT3, and 5.0% to 6.9% pT4 tumors (27, 28).

To confirm that our sample displays the typical clinical course of patients with bladder cancer, we calculated Kaplan-Meier curves for overall survival depending on the established predictive parameter "pathologic stage." As shown in Fig. 1A, overall survival was significantly dependent on pathologic stage (P < 0.0001) and survival rates were comparable with published data (3, 29). Moreover, as mortality increases with increasing age (29), we used the receiver operating characteristic curve analysis (see Materials and Methods) to define a cutoff value of 54 years to discriminate survival rates. Figure 1B clearly shows that the overall survival is increased in patients younger than 54 years compared with older patients.



View larger version (21K):
[in this window]
[in a new window]
  		Figure 1. Overall survival for the period of 5 years of follow-up based on Kaplan-Meier curves for 254 patients with bladder cancer based on different tumor stages (A) or age groups (B).

 
We next analyzed possible associations between demographic data and genotypes of the T393C polymorphism (Table 2). Men were affected three times more often than women, which is compatible with data from the literature (1, 28, 30), but neither gender nor smoking habits were related to genotypes. Age at primary diagnosis was slightly higher in TT genotypes (65.1 years) compared with CC genotypes (61.4 years) with TC genotypes showing intermediate values (63.1 years, P = 0.059 ANOVA). Tumor grade was not significantly associated with T393C genotypes. On the other hand, the comparison of pathologic stages and genotype distribution showed a significant relationship between genotype and pathologic stage at the time of initial diagnosis. Only 22.9% with pTa had CC genotypes, whereas 56.5% of pT4 patients had CC genotypes (P = 0.021).


View this table:
[in this window]
[in a new window]
  		Table 2. Genotype distribution, demographic characteristics, smoking habit, and grade and stage of the tumor at primary diagnosis in the 254 patients with bladder cancer

 
Clinical Outcome by GNAS1 T393C Genotypes
Progression, metastasis, and tumor-related mortality dependent on T393C genotypes were analyzed using Kaplan-Meier estimates (Table 3) and survival curves (Fig. 2). Because the 393C allele was significantly associated with advanced disease at the time of diagnosis (Table 2), log-rank tests for clinical outcome were adjusted for clinical stage and separate probabilities for the subgroups of superficial and muscle invasive carcinoma were calculated (Table 3).


View this table:
[in this window]
[in a new window]
  		Table 3. Progression-free survival, metastatic-free survival, and survival (or no tumor-related death) of patients with bladder cancer

 


View larger version (18K):
[in this window]
[in a new window]
  		Figure 2. Progression (A), metastasis (B), and survival (C) for the period of 5-year follow-up based on Kaplan-Meier curves for 254 patients with bladder cancer on different T393C genotypes. P values for log-rank statistics were calculated for linear comparison of all genotypes and adjusted for pathologic stage.

 
Progression was significantly dependent on the T393C genotype with an apparent gene-dose effect (P = 0.011; Fig. 2A). GNAS1 393C homozygous patients displayed a higher risk for tumor progression than T393 homozygous patients, with heterozygous patients being at intermediate risk (hazard ratios: CC versus TT: 2.0, 95% CI 1.1-3.1, P = 0.015; CT versus TT: 1.5, 95% CI 0.9-2.4, P = 0.15).

Time to metastasis was also significantly associated with genotypes of the T393C polymorphism (P = 0.001; Fig. 2B). Whereas 393C homozygous patients were at higher risk for the development of metastases, T393 homozygosity is associated with a protective effect and heterozygous subjects were at intermediate risk (hazard ratios: CC versus TT: 3.7, 95% CI 1.5-5.6, P = 0.002; CT versus TT: 2.5, 95% CI 1.1-4.2, P = 0.03). The same observation emerged for the time to tumor-related death and the T393C polymorphism (P = 0.014; Fig. 2C). GNAS1 393C homozygous patients were at higher risk for death from bladder cancer compared with T393 homozygous individuals, with heterozygous patients being at intermediate risk (hazard ratio: CC versus TT: 2.7, 95% CI 1.2-4.6, P = 0.013; CT versus TT: 2.2, 95% CI 1.0-3.8, P = 0.039). The proportions of progression-free, metastases-free, and overall survival are given in Table 3, which shows that the probability of survival or being free of progression and metastases is reduced with increasing numbers of C alleles for both superficial and muscle-invasive stages.

Smoking is a known risk factor for the development of bladder cancer and an interaction between the T393C polymorphisms and smoking on hypertension has been reported for a Japanese population (23). We, therefore, calculated genotype-dependent Kaplan-Meier curves separately for current smokers and nonsmokers and found that genotype effects were not significantly different in smokers versus nonsmokers (data not shown).

Multivariate analysis, including age at diagnosis, gender, pathologic stage, and T393C genotypes, revealed that patients >54 years at time of diagnosis were at higher risk for tumor-related death than younger patients (hazard ratio, 2.37; 95% CI, 1.21-4.65; P = 0.012). Most interestingly, besides pathologic stage as a known established risk factor, the T393C polymorphism was an independent risk factor for progression, metastasis, and tumor-related death (Table 4). Patients with CC genotype had hazard ratios of 1.94 (95% CI, 1.11-3.38; P = 0.020) for progression, 3.49 (95% CI, 1.46-8.37; P = 0.005) for metastasis, and 2.49 (95% CI, 1.09-5.71; P = 0.031) for tumor-related death compared with the reference group consisting of T393 homozygous individuals. Heterozygous patients were at intermediate risk.


View this table:
[in this window]
[in a new window]
  		Table 4. Multivariate Cox proportional hazard model for progression, metastasis, and tumor-related death in 254 bladder cancer patients

 
When we tested a potential interaction between the T393C polymorphism and smoking habits in this multivariate model, we found no significant interaction for progression (P = 0.993), metastasis (P = 0.207), or tumor-related death (P = 0.454), indicating that genotype-dependent clinical outcome is independent of smoking status.

Potential Function of the T393C Polymorphism
Increased expression of G{alpha}s has been shown to activate the adenylyl cyclase signal transduction cascade, resulting in an accumulation of cAMP (15). We, therefore, tested the hypothesis whether genotypes of the GNAS1 T393C polymorphism are associated with altered G{alpha}s expression. To this end, we measured G{alpha}s mRNA expression by means of quantitative real-time PCR using 38 tumor tissue specimens derived from different patients with bladder cancer. G{alpha}s mRNA expression was significantly different between genotypes (P = 0.017; linear ANOVA) with highest expression associated with the TT genotype, followed by TC and CC genotypes (Fig. 3A). To investigate whether genotype-dependent G{alpha}s mRNA expression could be a general phenomenon also in nontumor tissue, we measured its expression in adipose tissue and heart. Similar genotype-dependent G{alpha}s mRNA expression was observed in these tissues with an apparent gene-dose effect in adipose tissue (P = 0.017; Fig 3B) and a comparable trend in human heart tissue that did not reach statistical significance possibly due to the small sample number (P = 0.150; Fig. 3B). These data, therefore, suggest a general mechanism on G{alpha}s mRNA expression associated with GNAS1 genotypes.



View larger version (14K):
[in this window]
[in a new window]
  		Figure 3. Quantitative real-time PCR with mRNA from TCC of the bladder (n = 38), adipose (n = 45), and heart (n = 15) tissue stratified by GNAS1 T393C genotypes. Relative G{alpha}s mRNA expression was measured by two-step real-time PCR with hß-Actin as internal control and calculated as 2–[Ct(G{alpha}s) – Ct(ß-actin)]. G{alpha}s mRNA expression was highest in TT genotypes with significantly different expression levels in TCC (P = 0.0174) and adipose tissue (P = 0.0174) between genotypes.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The biology of initiation and progression of TCC is complex and its interindividual course is highly variable. Although clinical T stage (TNM) statistically correlates with outcome in a large percentage of patients, prediction of the individual course of disease in patients with identical tumor stages would require the availability of additional biomarkers. This could comprise presence or absence of somatic mutations in specific genes, gene expression profiles, but also genetic host factors (e.g., germ line single nucleotide polymorphisms). As an example, genetic instability and the accumulation of synergistically acting genetic lesions mainly involving p53, p21, retinoblastoma, and growth factors correlate with the progression of TCC (5, 10, 31, 32). In addition, a recent report examined combined p53, p21, and pRb expression in the progression of bladder cancer and detected additive effects of these alterations (33). Nevertheless, although these authors could predict the outcome for patients with tumors that show multiple alterations (p53, p21, or pRb), they also showed that it was still difficult to predict the outcome for patients with tumors that showed relatively few alterations. It was, therefore, suggested that progression of these tumors might be governed by alternative proteins or pathways (33).

We have investigated whether a genetic host factor, the common T393C polymorphism in the gene GNAS1 that encodes the G proteins subunit, may be predictive for clinical outcome in patients with TCC. The results presented here show that time to progression, metastasis, and tumor-related death was significantly accelerated in CC genotypes compared with TC or TT genotypes. Importantly, although 393C allele carriers presented at an advanced stage at first diagnosis, subanalysis of genotype-dependent progression at different stages (superficial and muscle-invasive stage), as well as log-rank statistics adjusted for pathologic stage, suggested a gene-dose effect for C-allele carriers with shorter time to progression, metastasis, and tumor-related death (Table 3). Moreover, the T393C polymorphism was an independent risk factor for clinical outcome when using staging as a covariate with the highest risk for an unfavorable clinical course in CC genotypes (Table 4). It should be emphasized here that the magnitude of the risk associated with C-allele carriage was not significantly different from that of stage, suggesting that genotyping of this polymorphism in patients with TCC could be of clinical relevance provided that our data are replicated by independent studies. Interestingly, older age (>54 years) was an independent risk factor for tumor-related death, whereas no correlation between gender and clinical outcome was observed. The question remains to be answered to what extent our sample is representative for patients with bladder cancer in Germany. According to available epidemiologic surveys, most cases (~70%) are classified as superficial cancers at the time of first detection (28, 29). In contrast, our sample showed a significant enrichment of patients with higher staging and grading (see Table 1). This discrepancy arises from the following facts: (a) Our study population was recruited from patients treated at our university hospital, which specializes in the treatment of advanced tumors, whereas less advanced cancers are frequently treated by primary urologists. (b) Samples for genotyping were obtained predominantly from patients undergoing cystectomy due to invasive bladder cancer. In contrast, superficial bladder cancer is frequently treated by transurethral resection and obtaining sufficient tumor material from these patients is more difficult. Thus, there is a selection bias that explains why staging and grading of our patients differs from that found in population-based surveys. We have, nevertheless, no evidence to suggest that this selection bias has a major impact on the results described here as we found in our sample the known increased mortality of older patients and those with increased tumor stages (Fig. 1). Nevertheless, our findings will have to be replicated by independent studies until these results can be universally accepted.

The observed associations raise the question about the molecular mechanism(s) potentially explaining the differences in clinical outcome of patients with different GNAS1 genotypes. The T393C polymorphism located in exon 5 of the GNAS1 gene is synonymous (i.e., it neither affects the encoded amino acid sequence nor is it located in the promoter region). However, genotypes are significantly associated with G{alpha}s mRNA expression, with TT genotypes displaying highest expression not only in urothelial tissue but also in adipose and heart tissue, suggesting a general mechanism of increased G{alpha}s expression in TT genotypes (Fig. 3). This result would, therefore, be compatible to recent studies where an association of the T393C polymorphism to hypertension was described (21-23). Unfortunately, the small size of tissue specimens available from each patient prevented more direct assessment of G{alpha}s expression through Western blot analysis. One potential explanation for the association between the T393C polymorphism and G{alpha}s mRNA expression would be the existence of yet unidentified polymorphisms in regulatory regions of GNAS1 (e.g., in the promoter), which are in linkage disequilibrium with the T393C polymorphism. The detection of such mutations was beyond the scope of the present study. However, the availability of enhanced PCR techniques, like "slow-down PCR," should now facilitate the sequencing of the GC-rich promoter regions of GNAS1, which was previously impeded by technical problems (34). On the other hand, the T393C polymorphism itself could influence the stability of the G{alpha}s transcript, which then could result in altered mRNA expression. For example, synonymous polymorphisms in the human DRD2 gene alter the predicted mRNA folding, lead to a decrease in mRNA stability and translation, and dramatically change dopamine-induced up-regulation of DRD2 expression (35).

Data from in vitro experiments suggest that increased expression of G{alpha}s possibly enhances apoptosis (15, 16, 36). The second messenger cAMP, which is generated by activated G{alpha}s, seems to play a major role in this proapoptotic process. cAMP is able to inhibit the physiologic actions of growth factors (37) and to block the transformation phenotype in selected malignant cells (38). For example, in fibroblasts and smooth muscle cells, cAMP inhibits mitogen-activated protein kinase activation by growth factors (39, 40) and during anchorage-independent cell growth (41). These growth-inhibitory actions are thought to be mediated by G protein pathways that regulate cAMP (38) and the cAMP-dependent protein kinase A (37).

We show here a significantly increased G{alpha}s mRNA expression in tumor tissue from patients homozygous for the 393T allele (Fig. 3). As a working hypothesis, these results are compatible with increased apoptosis in 393T allele carriers, which is especially important in malignant cells and could, therefore, contribute to a more favorable clinical course in these patients.

In conclusion, our data suggest that the GNAS1 T393C polymorphism is independently associated with disease progression in patients with bladder cancer.

It would now be important to replicate these dates in independent studies and to investigate a potential role of this polymorphisms in other cancer entities.


   Acknowledgments
 
We thank Karl Worm for his excellent assistance with the real-time PCR experiments and Markus Neuhäuser for critical reading of the manuscript.


   Footnotes
 
Grant support: Grant from Deutsche Forschungsgemeinschaft.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: U. Frey and A. Eisenhardt contributed equally to this work.

Received 10/ 1/04; revised 12/14/04; accepted 12/21/04.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5–26.[Abstract/Free Full Text]
  2. Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 2000;27:1–13.[CrossRef][Medline]
  3. Borden LS Jr, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol 2003;15:227–33.[CrossRef][Medline]
  4. Sidransky D, Von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991;252:706–9.[Abstract/Free Full Text]
  5. Cordon-Cardo C, Wartinger D, Petrylak D, et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992;84:1251–6.[Abstract/Free Full Text]
  6. Schairer C, Hartge P, Hoover RN, Silverman DT. Racial differences in bladder cancer risk: a case-control study. Am J Epidemiol 1988;128:1027–37.[Abstract/Free Full Text]
  7. Van Brussel JP, Mickisch GH. Prognostic factors in renal cell and bladder cancer. BJU Int 1999;83:902–8.[Medline]
  8. Reznikoff CA, Belair CD, Yeager TR, et al. A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 1996;23:571–84.[Medline]
  9. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259–64.[Abstract/Free Full Text]
  10. Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998;58:1090–4.[Abstract/Free Full Text]
  11. Myklebust JH, Josefsen D, Blomhoff HK, et al. Activation of the cAMP signaling pathway increases apoptosis in human B-precursor cells and is associated with downregulation of Mcl-1 expression. J Cell Physiol 1999;180:71–80.[CrossRef][Medline]
  12. Srivastava RK, Srivastava AR, Cho-Chung YS, Longo DL. Synergistic effects of retinoic acid and 8-Cl-cAMP on apoptosis require caspase-3 activation in human ovarian cancer cells. Oncogene 1999;18:1755–63.[CrossRef][Medline]
  13. Yan L, Herrmann V, Hofer JK, Insel PA. ß-adrenergic receptor/cAMP-mediated signaling and apoptosis of S49 lymphoma cells. Am J Physiol Cell Physiol 2000;279:C1665–74.[Abstract/Free Full Text]
  14. Dohlman HG, Thorner J, Caron MG, Lefkowitz RJ. Model systems for the study of seven-transmembrane-segment receptors. Annu Rev Biochem 1991;60:653–88.[CrossRef][Medline]
  15. Yang X, Lee FY Sr, Wand GS. Increased expression of Gs({alpha}) enhances activation of the adenylyl cyclase signal transduction cascade. Mol Endocrinol 1997;11:1053–61.[Abstract/Free Full Text]
  16. Krumins AM, Barber R. Examination of the effects of increasing Gs protein on ß2-adrenergic receptor, Gs, and adenylyl cyclase interactions. Biochem Pharmacol 1997;54:61–72.[CrossRef][Medline]
  17. Collins MT, Chebli C, Jones J, et al. Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. J Bone Miner Res 2001;16:806–13.[CrossRef][Medline]
  18. Collins MT, Sarlis NJ, Merino MJ, et al. Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs{alpha} mutations. J Clin Endocrinol Metab 2003;88:4413–7.[Abstract/Free Full Text]
  19. Landis CA, Masters SB, Spada A, et al. GTPase inhibiting mutations activate the {alpha} chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989;340:692–6.[CrossRef][Medline]
  20. Lyons J, Landis CA, Harsh G, et al. Two G protein oncogenes in human endocrine tumors. Science 1990;249:655–9.[Abstract/Free Full Text]
  21. Jia H, Hingorani AD, Sharma P, et al. Association of the G(s){alpha} gene with essential hypertension and response to ß-blockade. Hypertension 1999;34:8–14.[Abstract/Free Full Text]
  22. Chen Y, Nakura J, Jin JJ, et al. Association of the GNAS1 gene variant with hypertension is dependent on alcohol consumption. Hypertens Res 2003;26:439–44.[Medline]
  23. Abe M, Nakura J, Yamamoto M, et al. Association of GNAS1 gene variant with hypertension depending on smoking status. Hypertension 2002;40:261–5.[Abstract/Free Full Text]
  24. Sobin LH, Wittekind C. UICC International Union Against Cancer. TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002. p. 199–202.
  25. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:1–11.
  26. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561–77.[Abstract/Free Full Text]
  27. Brauers A, Jakse G. Epidemiology and biology of human urinary bladder cancer. J Cancer Res Clin Oncol 2000;126:575–83.[CrossRef][Medline]
  28. Fischer CG, Waechter W, Kraus S, et al. Urologic tumors in the Federal Republic of Germany: data on 56,013 cases from hospital cancer registries. Cancer 1998;82:775–83.[CrossRef][Medline]
  29. Madeb R, Messing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol 2004;22:86–92.[Medline]
  30. Aben KK, Kiemeney LA. Epidemiology of bladder cancer. Eur Urol 1999;36:660–72.[Medline]
  31. Stein JP, Ginsberg DA, Grossfeld GD, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998;90:1072–9.[Abstract/Free Full Text]
  32. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85:53–9.[Abstract/Free Full Text]
  33. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004;22:1007–13.[Abstract/Free Full Text]
  34. Bachmann HS, Siffert W, Frey UH. Successful amplification of extremely GC-rich promoter regions using a novel "slowdown PCR" technique. Pharmacogenetics 2003;13:759–66.[CrossRef][Medline]
  35. Duan J, Wainwright MS, Comeron JM, et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003;12:205–16.[Abstract/Free Full Text]
  36. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the ß2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997;390:88–91.[CrossRef][Medline]
  37. Indolfi C, Avvedimento EV, Di LE, et al. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat Med 1997;3:775–9.[CrossRef][Medline]
  38. Chen J, Iyengar R. Suppression of Ras-induced transformation of NIH 3T3 cells by activated G{alpha}s. Science 1994;263:1278–81.[Abstract/Free Full Text]
  39. Cook SJ, McCormick F. Inhibition by cAMP of Ras-dependent activation of Raf. Science 1993;262:1069–72.[Abstract/Free Full Text]
  40. Graves LM, Bornfeldt KE, Raines EW, et al. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci U S A 1993;90:10300–4.[Abstract/Free Full Text]
  41. Howe AK, Juliano RL. Regulation of anchorage-dependent signal transduction by protein kinase A and p21-activated kinase. Nat Cell Biol 2000;2:593–600.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Eur Heart JHome page
U. H. Frey, W. Lieb, J. Erdmann, D. Savidou, G. Heusch, K. Leineweber, H. Jakob, H.-W. Hense, H. Lowel, N. H. Brockmeyer, et al.
Characterization of the GNAQ promoter and association of increased Gq expression with cardiac hypertrophy in humans
Eur. Heart J., April 1, 2008; 29(7): 888 - 897.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. F. Lehnerdt, P. Franz, A. Zaqoul, K. J. Schmitz, S. Grehl, S. Lang, K. W. Schmid, W. Siffert, K. Jahnke, and U. H. Frey
Overall and Relapse-Free Survival in Oropharyngeal and Hypopharyngeal Squamous Cell Carcinoma Are Associated with Genotypes of T393C Polymorphism of the GNAS1 Gene
Clin. Cancer Res., March 15, 2008; 14(6): 1753 - 1758.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y.-H. Lin, J. Friederichs, M. A. Black, J. Mages, R. Rosenberg, P. J. Guilford, V. Phillips, M. Thompson-Fawcett, N. Kasabov, T. Toro, et al.
Multiple Gene Expression Classifiers from Different Array Platforms Predict Poor Prognosis of Colorectal Cancer
Clin. Cancer Res., January 15, 2007; 13(2): 498 - 507.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
S. Hahn, U. H Frey, W. Siffert, S. Tan, K. Mann, and O. E Janssen
The CC genotype of the GNAS T393C polymorphism is associated with obesity and insulin resistance in women with polycystic ovary syndrome.
Eur. J. Endocrinol., November 1, 2006; 155(5): 763 - 770.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. H. Frey, H. Nuckel, L. Sellmann, D. Siemer, R. Kuppers, J. Durig, U. Duhrsen, and W. Siffert
The GNAS1 T393C Polymorphism Is Associated with Disease Progression and Survival in Chronic Lymphocytic Leukemia.
Clin. Cancer Res., October 1, 2006; 12(19): 5686 - 5692.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. H. Frey, G. Lummen, T. Jager, K.-H. Jockel, K. W. Schmid, H. Rubben, N. Muller, W. Siffert, and A. Eisenhardt
The GNAS1 T393C Polymorphism Predicts Survival in Patients with Clear Cell Renal Cell Carcinoma
Clin. Cancer Res., February 1, 2006; 12(3): 759 - 763.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. H. Frey, H. Alakus, J. Wohlschlaeger, K. J. Schmitz, G. Winde, H. G. van Calker, K.-H. Jockel, W. Siffert, and K. W. Schmid
GNAS1 T393C Polymorphism and Survival in Patients with Sporadic Colorectal Cancer
Clin. Cancer Res., July 15, 2005; 11(14): 5071 - 5077.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frey, U. H.
Right arrow Articles by Siffert, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frey, U. H.
Right arrow Articles by Siffert, W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation